by Dan Roberts [It was reported on 2/9/12 that Phase III of this study did not meet it’s primary endpoint at 2 years. The information in this article describes the progress up to that point.] NeoVista, Inc. announced on June 17, 2007 the official commencement of the CABERNET (Cnv secondary to Amd treated with BEta [Read More]
News
New Treatment for Dry AMD Using HuCNS Stem Cells
by Dan Roberts February 2, 2012 StemCells, Inc. announced on February 2, 2012 that the FDA has authorized a Phase I/II clinical trial of a new method using stem cells from the brain to prevent degeneration of the macula in dry AMD patients. Purified human neural stem cells (HuCNS-SC) will be administered by a single [Read More]
Degenerative Myopia: a Review of its Nature and Current Treatment
by Brian Ward, Ph.D., M.D. December 2011 Degenerative myopia deserves our recognition as one of the truly neglected areas of ophthalmology. It is reported to be the seventh ranking cause of legal blindness in the United Sates of America the fourth ranking cause in Hong Kong and the second in parts of China and Japan. [Read More]
An Examination of Sensory Contributions to Independent Activities of Daily Living
This paper is in PDF format. To download it, select this link.
Artificial Lighting and the Blue Light Hazard
(The Facts About Lighting and Vision) by Dan Roberts, Founding Director Macular Degeneration Support Originally published on MDSupport, updated October 3, 2011) Contents Introduction What Is Light? The Blue Light Hazard Terms Referring to Measurement of Light Types of Lamps The Problem With Full-Spectrum Lamps Market Survey Summary Discussion Safe Options Live Comparison of Representative [Read More]